O. M. Blanco-c, W. S. Liu-s-m, and C. Cu, National Trends in the Office-Based Treatment of Children, Adolescents, and Adults With Antipsychotics, Arch Gen Psychiatry, pp.1-10, 2012.

M. Ar and T. G. , Summary of the comparative effectiveness review on off-label use of atypical antipsychotics, J Manag Care Pharm JMCP, vol.18, pp.1-20, 2012.

M. M. , M. Ar, and H. J. , Off-Label Use of Atypical Antipsychotics: An Update, p.66081, 2011.

L. Dl and R. R. , Off-label use of antipsychotic medications in Medicaid, Am J Manag Care, vol.18, pp.109-117, 2012.

P. J. , H. A. , A. Gc, and C. R. , Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, Psychiatr Serv Wash DC, vol.63, pp.83-86, 1998.

B. Agmb, Substantial Changes in Prescription Recommendations for Bipolar Disorder in Canada: 2002-2010, Can J Psychiatry, vol.57, pp.263-268, 2012.

G. Jr and M. Dj, Treatment of bipolar disorder, Lancet, vol.381, pp.1672-1682, 2013.

C. Jr and K. De, Bipolar Drug Development: Are We Getting Closer to the Real World?, Am J Psychiatry, vol.165, pp.1234-1236, 2008.

G. H. , V. E. , and G. Gm, The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression, World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry, vol.11, pp.81-109, 2010.

G. H. , V. E. , and G. Gm, The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder, World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry, vol.14, pp.154-219, 2013.

G. Gm, Evidence-based guidelines for treating bipolar disorder: revised second edition?recommendations from the British Association for Psychopharmacology, J Psychopharmacol (Oxf), vol.23, pp.346-388, 2009.

B. Mf, L. G. , L. L. , F. , E. Guia et al., Clinical practice guideline on bipolar disorder: drug and psychosocial therapy, Asociación Española de Neuropsiquiatría]. Med Clínica, vol.141, pp.305-306, 2013.

P. A. , B. T. , and F. P. Bauer-m, The diagnosis and treatment of bipolar disorder: recommendations from the current s3 guideline, Dtsch Ärztebl Int, vol.110, pp.92-100, 2013.

D. Gesellschaft, . Bipolare, D. Störungen, . Gesellschaft, . Psychiatrie et al., S3-Leitlinie zur Diagnostik und Therapie bipolarer Störungen

Y. Ln, K. Sh, and P. Sv, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013, Bipolar Disord, vol.15, pp.1-44, 2013.

M. Rs, M. Da, L. P. , and J. J. , Treating bipolar disorder. Evidence-based guidelines for family medicine, Can Fam Physician Médecin Fam Can, vol.50, pp.388-394, 2004.

A. Psychiatric, Practice guideline for the treatment of patients with bipolar disorder (revision), Am J Psychiatry Suppl Pract Guidel Treat Patients With, vol.159, pp.1-50, 2002.

S. T. , D. Eb, and H. Rma, The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder, J Clin Psychiatry, vol.66, pp.870-886, 2005.

V. Gh, S. S. , and G. Bonetto-g, Argentine consensus on the treatment of bipolar disorders], Vertex B Aires Argent, vol.16, pp.3-24, 2005.

M. Gs, B. Dm, and M. R. , Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder, Bipolar Disord, vol.14, issue.2, pp.1-21, 2012.

M. Gs, B. Dm, and M. R. , Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder, Bipolar Disord, vol.14, pp.1-21, 2012.

M. Ym, C. Hn, and C. Ks, Ministry of Health clinical practice guidelines: bipolar disorder, Singapore Med J, vol.52, issue.919, pp.914-918, 2011.

K. S. Kato-t, T. T. , Y. K. , C. For, . Guidelines et al., Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, Psychiatry Clin Neurosci, vol.67, pp.285-300, 2012.

S. Yc, M. Kj, and Y. , Korean medication algorithm for bipolar disorder: Second revision. Asia-Pac Psychiatry Off J Pac Rim Coll Psychiatr Published Online First, 2013.

G. Fk and J. Kr, Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, 2007.

T. M. and F. E. Bowden-cl, The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders, Bipolar Disord, vol.11, pp.453-473, 2009.

P. Rh, Predictors of Recurrence in Bipolar Disorder: Primary Outcomes From the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), Am J Psychiatry, vol.163, pp.217-224, 2006.

V. E. Blasco-colmenares-e, F. Ml, L. Jm, and M. E. Moreno-manzanaro-m, Clinical management and burden of bipolar disorder: a multinational longitudinal study (WAVE-bd study), BMC Psychiatry, vol.11, p.58, 2011.

W. Rh, N. Wa, N. A. , H. A. , and P. B. , TRIAL 144 STUDY INVESTIGATORS. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study), J Clin Psychiatry, vol.72, pp.1452-1464, 2011.

N. Wa and W. Rh, The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144), Bipolar Disord, vol.15, pp.100-109, 2013.

T. M. , C. Jr, and S. Gs, Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine, Am J Psychiatry, vol.163, pp.247-256, 2006.

T. M. , S. Vk, C. Jr, S. Gs, and . Bowden-cl, Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder, J Affect Disord, vol.116, pp.43-50, 2009.

K. Pe-jr, C. Jr, and M. Rd, A randomized, double-blind, placebocontrolled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder, J Clin Psychiatry, vol.67, pp.626-637, 2006.

K. Pe-jr, C. Jr, and M. Rs, Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo, J Clin Psychiatry, vol.68, pp.1480-1491, 2007.

K. Pe-jr, M. R. , and T. S. , A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania, Am J Psychiatry, vol.160, pp.1651-1658, 2003.

M. Dj, M. C. , and E. Jm, Aripiprazole monotherapy in patients with rapidcycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study, Int J Clin Pract, vol.62, pp.679-687, 2008.

T. Ac, R. Nz, J. Jn, P. Pi, S. Gi et al., Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature, PLoS Med, vol.8, p.1000434, 2011.

Y. Ln, F. Kn, and R. Z. , Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode, J Affect Disord, vol.147, pp.365-372, 2013.

B. W. Woo-y and C. M. , Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial, Human Psychopharmacology: Clinical and Experimental, vol.133, issue.Suppl., pp.543-553, 2011.
DOI : 10.1002/hup.1240

M. S. , Y. Ah, and C. A. , A double-blind, placebo-controlled study with acute and continuation phase of Quetiapine and Paroxetine in adults with bipolar depression (Embolden II), Eur Psychiatry, vol.23, p.239, 2008.

Y. Ah, C. A. , O. B. , P. B. , and B. M. , A double-blind, placebocontrolled study with acute and continuation phase of Quetiapine and Lithium in adults with bipolar depression (Embolden I), Eur Psychiatry, vol.23, p.239, 2008.

Y. Ah, M. Sl, O. B. , P. B. , and E. I. , EMBOLDEN II (D1447C00134) INVESTIGATORS. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder, D1447C00001), pp.96-112, 2014.

M. Sl, W. Rh, and C. W. , A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)

U. De-york, Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials, Int J Neuropsychopharmacol, vol.14, pp.1029-1049, 2011.

C. A. , R. J. , and G. Jr, Olanzapine in the long-term treatment of bipolar disorder: A systematic review and meta-analysis, J Psychopharmacol (Oxf), vol.24, pp.1729-1738, 2010.

T. M. , K. Ta, and Z. Ca, Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study, Am J Psychiatry, vol.160, pp.1263-1271, 2003.

A. Ac, R. M. , V. S. , and M. E. , Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder, J Clin Psychopharmacol, vol.24, pp.454-456, 2004.

F. E. , K. Ai, B. P. , F. L. , F. A. et al., The message of the survival curves: I. Composite analysis of long-term treatment studies in bipolar disorder, Neuropsychopharmacol Hung Magy Pszichofarmakológiai Egyes Lapja Off J Hung Assoc Psychopharmacol, vol.14, pp.155-164, 2012.

L. J. , C. Kn, and B. Js, Psychotropic drug prescription patterns among patients with bipolar I disorder, Bipolar Disord, vol.2, pp.120-130, 2000.

B. Md, L. Pd, A. Pd, G. Dph, Z. Mph et al., Patterns of Psychotropic Drug Prescription for U.S. Patients With Diagnoses of Bipolar Disorders, Psychiatr Serv, vol.58, pp.85-91, 2007.

F. Kn, K. S. , and A. O. , Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry, Eur Arch Psychiatry Clin Neurosci, vol.262, issue.1, pp.1-48, 2012.

L. S. , C. C. , A. D. Engel-rr, L. C. , and D. Jm, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, Lancet, vol.373, pp.31-41, 2009.

M. Aj, V. D. , S. K. Van-winkel-r, and Y. W. De, Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis, Schizophr Bull, vol.39, pp.306-318, 2013.

C. Cu, F. Am, K. Jm, and M. P. , Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics, Bipolar Disord, vol.10, pp.788-797, 2008.

Z. Ca and T. M. , Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients, Am J Psychiatry, vol.161, pp.169-171, 2004.

T. M. , G. Jf, and G. Am, A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania, Arch Gen Psychiatry, vol.60, pp.1218-1226, 2003.

D. Vv, B. , and S. Mg, Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview, Acta Psychiatr Scand, vol.126, pp.315-331, 2012.

A. Ö. Bourne-c and B. , Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis, Acta Psychiatrica Scandinavica, vol.2, issue.3
DOI : 10.1111/acps.12133

H. J. and B. Rj, Suicidal risk during treatment with clozapine: a meta-analysis, Schizophr Res, vol.73, pp.139-145, 2005.

Y. Bi and C. Ym, Impact of psychotropic drugs on suicide and suicidal behaviors, Bipolar Disord, vol.15, pp.594-621, 2013.

Y. Bi, K. Rj, and M. J. , Bipolar pharmacotherapy and suicidal behavior Part 3: impact of antipsychotics, J Affect Disord, vol.103, pp.23-28, 2007.

A. Ep, C. P. , and H. M. , Suicide attempts in veterans with bipolar disorder during treatment with lithium, divalproex, and atypical antipsychotics, J Affect Disord, vol.145, pp.77-82, 2013.

U. Yood-m, D. G. , and Q. Cp, Epidemiologic study of aripiprazole use and the incidence of suicide events, Pharmacoepidemiology and Drug Safety, vol.18, issue.15, pp.1124-1130, 2010.
DOI : 10.1002/pds.2047

D. Zelicourt-m, D. R. , and V. H. , Bipolar I disorder in France: prevalence of manic episodes and hospitalisation-related costs, Encéphale, vol.29, pp.248-253, 2003.

G. and D. R. De, In-patient care costs of patients with bipolar I disorder: a comparison between two European centers, J Affect Disord, vol.121, pp.152-155, 2010.

O. Jp and L. E. , Manic episodes: the direct cost of a three-month period following hospitalisation, Eur Psychiatry J Assoc Eur Psychiatr, vol.17, pp.278-286, 2002.

D. R. , T. J. , E. C. Friedman-s, and G. , Coût du trouble bipolaire : revue de la littérature, Encéphale, vol.32, pp.18-25, 2006.

D. Gupta-r and G. Jf, Annual cost of bipolar disorder to UK society, The British Journal of Psychiatry, vol.180, issue.3, pp.227-233, 2002.
DOI : 10.1192/bjp.180.3.227

N. P. , D. Carvalho-w, and B. P. , Pratiques thérapeutiques dans la prise en charge des patients souffrant de troubles bipolaires en France, Étude TEMPPO. L'Encéphale, vol.38, pp.75-85, 2012.

R. Kl, R. Km, and O. Ca, Adherence, Persistence of Use, and Costs Associated With Second-Generation Antipsychotics for Bipolar Disorder, Psychiatr Serv, vol.62, pp.1032-1040, 2011.

G. De-montleau-f, S. D. , and V. C. , Évaluation de la prescription d'antipsychotiques en médecine générale : conséquences métaboliques, Encéphale, vol.38, pp.453-459, 2012.

G. Fd, S. M. , R. K. , and W. , Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder, Clin Ther, vol.30, pp.1358-1374, 2008.

Q. Y. , F. Az, L. Gg, and C. Db, Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a Medicaid programme, Appl Health Econ Health Policy, vol.8, pp.167-177, 2010.

R. P. , S. Mw, D. R. , N. M. , and T. M. , Pharmacotherapy patterns in the treatment of bipolar disorder, Bipolar Disord, vol.4, pp.366-377, 2002.

V. H. , G. B. , and T. N. Bourgeois-m, A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients, J Affect Disord, vol.38, pp.81-87, 1996.

C. C. , S. K. , W. Ma, and S. J. , Comorbidities and mortality in bipolar disorder: A swedish national cohort study, JAMA Psychiatry, vol.70, pp.931-939, 2013.

J. Me, C. G. , and P. D. , Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database, Cardiovasc Psychiatry Neurol, vol.2013, p.647476, 2013.

B. Mc, B. P. , P. A. , and F. , The use of Atypical antipsychotics in French psychiatric hospitals, Pharm World Sci, vol.29, pp.551-556, 2007.

B. Jg, K. I. , J. Y. , Y. M. , F. R. et al., Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics, Am Health Drug Benefits, vol.5, pp.379-386, 2012.

W. Tc, T. E. , Q. P. , K. J. , and L. A. , Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder, J Med Econ, vol.12, pp.259-268, 2009.

. Le-coût-pour-la-société-est-important-en-france, le coût direct lié aux hospitalisations des patients bipolaires de type I a été estimé à 1,3 milliard d'euros par an pour l'année En, Notons que cette étude a été réalisée alors qu'aucun antipsychotique n'était utilisé en pratique courante dans le trouble bipolaire et que les calculs de coût ont été effectués pour une faible prévalence, 1999.

M. Étude-statistique-de-santé-publique-l-'assurance-maladie-publie-les-données, AM regroupant le volume et le montant des médicaments remboursés en France durant l'année écoulée [ 92 ] Ces chiffres nous permettent d'observer que les prescriptions d'antipsychotiques augmentent de manière importante chaque année. Le nombre de boîtes d'ABILIFY remboursées est passé de 427 661 boites en 2008 à 735 607 boites en 2010 sur une base de remboursement de 83 262 814 euros. Il y a donc eu une progression de +72% en 2 ans. En 2002, soit un an avant l'AMM pour le trouble bipolaire

«. La-publication-de-l-'assurance-maladie and . Médicaments-remboursables-délivrés-en-officine, Elle rapporte cette hausse à une « progression à la fois [liée] à leurs prescriptions (+7,3 %) et à un effet de structure important (augmentation de Risperdalconsta® LP [rispéridone à libération prolongée intramusculaire], Zyprexa® (olanzapine) et Abilify® (aripiprazole) au détriment des produits plus anciens, n°34 décembre 2010) [ 62 ] rapporte un hausse des dépenses liée aux antipsychotiques en 2009 par rapport à Notons que les deux traitements par voie orale cités sont les deux seuls antipsychotiques ayant l'AMM dans le trouble bipolaire. Nous pensons que ces deux événements concomitants doivent interpeller les professionnels de santé et motiver les recherches sur les prescriptions d'antipsychotique dans le trouble bipolaire, 2008.

L. Décrit-le-trouble-bipolaire-comme-une-pathologie-représentant-un-«-fardeau-de-santé-publique-[, ] compte-tenu de leur fréquence et de leur gravité. L'amélioration de leur prise en charge constitue un besoin de santé publique s

M. Olfson, C. Blanco, S. Liu, S. Wang, and C. Correll, National Trends in the Office-Based Treatment of Children, Adolescents, and Adults With Antipsychotics, Archives of General Psychiatry, vol.69, issue.12, 2012.
DOI : 10.1001/archgenpsychiatry.2012.647

H. Verdoux, M. Tournier, and B. Bégaud, Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies, Acta Psychiatrica Scandinavica, vol.27, issue.Suppl. 12, pp.4-10, 2010.
DOI : 10.1111/j.1600-0447.2009.01425.x

A. R. Maher and G. Theodore, Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics, Journal of Managed Care Pharmacy, vol.18, issue.5 Supp B, pp.1-20, 2012.
DOI : 10.18553/jmcp.2012.18.s5-b.1

M. Maglione, Off-Label Use of Atypical Antipsychotics: An Update, 2011.

D. L. Leslie and R. Rosenheck, Off-label use of antipsychotic medications in Medicaid, Am J Manag Care, vol.18, pp.109-117, 2012.

M. Vacheron-trystram, A. Braitman, S. Cheref, and L. Auffray, Antipsychotiques et troubles bipolaires, L'Enc??phale, vol.30, issue.5, pp.417-424, 2004.
DOI : 10.1016/S0013-7006(04)95456-5

J. Pillarella, A. Higashi, G. C. Alexander, and R. Conti, Trends in Use of Second-Generation Antipsychotics for Treatment of Bipolar Disorder in the United States, 1998???2009, Psychiatric Services, vol.63, issue.1, pp.83-86, 1998.
DOI : 10.1176/appi.ps.201100092

A. G. Bulloch, L. C. Bresee, C. A. Beck, and S. B. Patten, Substantial changes in prescription recommendations for bipolar disorder in Canada, Can J Psychiatry, vol.57, pp.2002-2010, 2012.

J. Hayes, Prescribing Trends in Bipolar Disorder: Cohort Study in the United Kingdom THIN Primary Care Database 1995???2009, PLoS ONE, vol.12, issue.12, p.28725, 2011.
DOI : 10.1371/journal.pone.0028725.t002

H. Verdoux, Antipsychotic use Patterns in Persons Initially Treated with Mood Stabilizers: A Naturalistic Study, Pharmacopsychiatry, vol.43, issue.01, pp.17-23, 2009.
DOI : 10.1055/s-0029-1237396

W. Greil, A. Häberle, P. Haueis, R. Grohmann, and S. Russmann, Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009, Journal of Affective Disorders, vol.136, issue.3, pp.534-542, 1994.
DOI : 10.1016/j.jad.2011.10.033

J. R. Geddes and D. J. Miklowitz, Treatment of bipolar disorder, The Lancet, vol.381, issue.9878, pp.1672-1682, 2013.
DOI : 10.1016/S0140-6736(13)60857-0

J. R. Calabrese and D. E. Kemp, Bipolar Drug Development: Are We Getting Closer to the Real World?, American Journal of Psychiatry, vol.165, issue.10, pp.1234-1236, 2008.
DOI : 10.1176/appi.ajp.2008.08060967

F. K. Goodwin, E. A. Whitham, and S. N. Ghaeini, Maintenance Treatment Study Designs in Bipolar Disorder Do They Demonstrate that Atypical Neuroleptics (Antipsychotics) are Mood Stabilizers?, CNS Drugs, vol.25, pp.819-827, 2011.

M. Adida, Troubles affectifs, antipsychotiques et thymor??gulateurs : innovations th??rapeutiques, L'Enc??phale, vol.36, pp.188-196, 2010.
DOI : 10.1016/S0013-7006(10)70056-7

R. M. Post, Acquired lithium resistance revisited: Discontinuation-induced refractoriness versus tolerance, Journal of Affective Disorders, vol.140, issue.1, pp.6-13, 2012.
DOI : 10.1016/j.jad.2011.09.021

M. Gitlin, Treatment-resistant bipolar disorder, Molecular Psychiatry, vol.160, issue.3, pp.227-240, 2006.
DOI : 10.1038/sj.mp.4001793

L. Judd and A. H. , A Prospective Investigation of the Natural History of the Long-term Weekly Symptomatic Status of Bipolar II Disorder, Archives of General Psychiatry, vol.60, issue.3, pp.261-269, 2003.
DOI : 10.1001/archpsyc.60.3.261

L. Judd and A. H. , The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder, Archives of General Psychiatry, vol.59, issue.6, pp.530-537, 2002.
DOI : 10.1001/archpsyc.59.6.530

H. Verdoux, A. Cougnard, S. Grolleau, and B. Bégaud, Impact of visits from pharmaceutical company representatives on antipsychotic prescription in primary care, Schizophrenia Research, vol.77, issue.1, pp.107-109, 2005.
DOI : 10.1016/j.schres.2005.02.001

G. Spielmans, The promotion of olanzapine in primary care: An examination of internal industry documents, Social Science & Medicine, vol.69, issue.1, pp.14-20, 2009.
DOI : 10.1016/j.socscimed.2009.05.001

A. Commission-de-la-transparence, 2012-04/anti_psychotiques_rapport.pdf> 24. afssaps mise au point de pharmacovigilance AP 04/2010. at <http://ansm.sante.fr/var/ansm_site/storage/original/application/6b3aa2489d62f9ee02e5e6200861b2e0. pdf> 25. Commissioner, O. of the. Safety Alerts for Human Medical Products -Antipsychotics, Conventional and Atypical

O. Commissioner and . Of-the, Safety Alerts for Human Medical Products -Abilify (aripiprazole). at <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/uc m153025.htm> 27. warning about Hyperglycemia and Atipical Antipsychotic Drugs

O. Commissioner and . Of-the, Safety Alerts for Human Medical Products -Antipsychotic drugs: Class Labeling Change -Treatment During Pregnancy and Potential Risk to Newborns. at <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/uc m244175.htm> 29. EMA 2013 priorities for drug safety research Long term safety effects of antipsychotics in patients with dementia, p.5, 2012.

J. Azorin, Mixed states with predominant manic or depressive symptoms: Baseline characteristics and 24-month outcomes of the EMBLEM cohort, Journal of Affective Disorders, vol.146, issue.3
DOI : 10.1016/j.jad.2012.09.021

P. Nuss, Pratiques th??rapeutiques dans la prise en charge des patients souffrant de troubles bipolaires en France. ??tude TEMPPO, L'Enc??phale, vol.38, issue.1, pp.75-85, 2012.
DOI : 10.1016/j.encep.2011.11.002

J. Azorin, Modalit??s de prise en charge de l???acc??s maniaque ou mixte aigu et ??volution ?? trois mois, L'Enc??phale, vol.36, issue.3, pp.226-235, 2010.
DOI : 10.1016/j.encep.2009.05.003

F. Gignoux-froment, F. De-montleau, D. Saravane, and C. Verret, ??valuation de la prescription d???antipsychotiques en m??decine g??n??rale??: cons??quences m??taboliques, L'Enc??phale, vol.38, issue.6, pp.453-459, 2012.
DOI : 10.1016/j.encep.2011.12.006

K. Merikangas and A. , Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication, Archives of General Psychiatry, vol.64, issue.5, pp.543-552, 2007.
DOI : 10.1001/archpsyc.64.5.543

B. Müller-oerlinghausen, A. Berghöfer, M. Bauer, and . Bipolar-disorder, Bipolar disorder, The Lancet, vol.359, issue.9302, pp.241-247, 2002.
DOI : 10.1016/S0140-6736(02)07450-0

P. Bebbington and R. Ramana, The epidemiology of bipolar affective disorder, Social Psychiatry and Psychiatric Epidemiology, vol.149, issue.Suppl 2, pp.279-292, 1995.
DOI : 10.1007/BF00805795

C. Faravelli, G. Degl-'innocenti, B. Aiazzi, L. Incerpi, G. Pallanti et al., Epidemiology of mood disorders: a community survey in Florence, Journal of Affective Disorders, vol.20, issue.2, pp.135-141, 1990.
DOI : 10.1016/0165-0327(90)90127-T

E. Szádóczky, Z. S. Papp, J. Vitrai, Z. Ríhmer, and J. Füredi, The prevalence of major depressive and bipolar disorders in Hungary, Journal of Affective Disorders, vol.50, issue.2-3, pp.153-162, 1998.
DOI : 10.1016/S0165-0327(98)00056-1

M. M. Weissman and J. K. Myers, Affective Disorders in a US Urban Community, Archives of General Psychiatry, vol.35, issue.11, pp.1304-1311, 1978.
DOI : 10.1001/archpsyc.1978.01770350030002

R. C. Kessler, Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication, Archives of General Psychiatry, vol.62, issue.6, pp.593-602, 2005.
DOI : 10.1001/archpsyc.62.6.593

D. Zélicourt and M. , Bipolar I disorder in France: prevalence of manic episodes and hospitalisationrelated costs], Encephale, vol.29, pp.248-253, 2003.

A. M. Gonzalez-pinto, In-patient care costs of patients with bipolar I disorder: A comparison between two European centers, Journal of Affective Disorders, vol.121, issue.1-2, pp.152-155, 2010.
DOI : 10.1016/j.jad.2009.05.010

J. P. Olié and E. Lévy, Manic episodes: the direct cost of a three-month period following hospitalisation, European Psychiatry, vol.17, issue.5, pp.278-286, 2002.
DOI : 10.1016/S0924-9338(02)00680-6

R. Dardennes, J. Thuile, C. Even, S. Friedman, and J. Guelfi, Co??t du trouble bipolaire : revue de la litt??rature, L'Enc??phale, vol.32, issue.1, pp.18-25, 2006.
DOI : 10.1016/S0013-7006(06)76133-4

D. Gupta, R. Guest, and J. , Annual cost of bipolar disorder to UK society, The British Journal of Psychiatry, vol.180, issue.3, pp.227-233, 2002.
DOI : 10.1192/bjp.180.3.227

C. Runge and H. Grunze, Annual costs of bipolar disorders in Germany], Nervenarzt, vol.75, pp.896-903, 2004.

L. Kleinman, Costs of Bipolar Disorder, PharmacoEconomics, vol.62, issue.8, pp.601-622, 2003.
DOI : 10.2165/00019053-200321090-00001

M. Ekman, Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode, PharmacoEconomics, vol.13, issue.4, pp.513-530, 2012.
DOI : 10.2165/11594930-000000000-00000

T. C. Woodward, E. Tafesse, P. Quon, and A. Lazarus, Cost Effectiveness of Adjunctive Quetiapine Fumarate Extended-Release Tablets with Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder, PharmacoEconomics, vol.66, issue.1, pp.751-764, 2010.
DOI : 10.2165/11538350-000000000-00000

L. Fajutrao, B. Paulsson, S. Liu, and J. Locklear, Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: Results of a markov model analysis, Clinical Therapeutics, vol.31, issue.1, pp.1456-1468, 2009.
DOI : 10.1016/j.clinthera.2009.06.009

T. C. Woodward, E. Tafesse, P. Quon, J. Kim, and A. Lazarus, Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder, Journal of Medical Economics, vol.12, issue.4, pp.259-268, 2009.
DOI : 10.3111/13696990903266612

J. Mckendrick, Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom, Journal of Psychopharmacology, vol.162, issue.7, pp.588-596, 2007.
DOI : 10.1177/0269881106068395

N. W. Calvert, S. P. Burch, A. Z. Fu, P. Reeves, and T. R. Thompson, The Cost-effectiveness of Lamotrigine in the Maintenance Treatment of Adults With Bipolar I Disorder, Journal of Managed Care Pharmacy, vol.12, issue.4, pp.322-330, 2006.
DOI : 10.18553/jmcp.2006.12.4.322

D. A. Revicki, Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: Results of a naturalistic clinical trial, Journal of Affective Disorders, vol.86, issue.2-3, pp.183-193, 2005.
DOI : 10.1016/j.jad.2005.01.002

B. Zhu, Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial, Current Medical Research and Opinion, vol.21, issue.4, pp.555-564, 2005.
DOI : 10.1185/030079905X38259

L. N. Yatham, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013, Bipolar Disorders, vol.131, issue.Suppl. 1, pp.1-44, 2013.
DOI : 10.1111/bdi.12025

P. Llorca, Dépistage et prise en charge du trouble bipolaire : Résultats. L'Encéphale 36, pp.86-102, 2010.

H. Grunze, The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression, The World Journal of Biological Psychiatry, vol.13, issue.1, pp.81-109, 2010.
DOI : 10.1016/j.biopsych.2004.03.013

G. M. Goodwin, Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology, Journal of Psychopharmacology, vol.23, issue.4, pp.346-388, 2009.
DOI : 10.1177/0269881109102919

L. N. Yatham, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009, Bipolar Disorders, vol.22, issue.Suppl. 1, pp.225-255, 2009.
DOI : 10.1111/j.1399-5618.2009.00672.x

G. S. Malhi, Clinical practice recommendations for bipolar disorder, Acta Psychiatrica Scandinavica, vol.2, issue.s434, pp.27-46, 2009.
DOI : 10.1111/j.1600-0447.2009.01383.x

G. M. Goodwin, ECNP consensus meeting. Bipolar depression. Nice, March 2007, European Neuropsychopharmacology, vol.18, issue.7, pp.535-549, 2007.
DOI : 10.1016/j.euroneuro.2008.03.003

T. Suppes, The Texas Implementation of Medication Algorithms, The Journal of Clinical Psychiatry, vol.66, issue.07, pp.870-886, 2005.
DOI : 10.4088/JCP.v66n0710

G. H. Vázquez, Argentine consensus on the treatment of bipolar disorders], Vertex, vol.16, pp.3-24, 2005.

R. S. Mcintyre, D. A. Mancini, P. Lin, and J. Jordan, Treating bipolar disorder. Evidence-based guidelines for family medicine, Can Fam Physician, vol.50, pp.388-394, 2004.

G. M. Goodwin and A. H. Young, The British Association for Psychopharmacology guidelines for treatment of bipolar disorder: a summary, J. Psychopharmacol. (Oxford), vol.17, pp.3-6, 2003.

A. Oshima, Treatment algorithms for mood disorders], Nihon Shinkei Seishin Yakurigaku Zasshi, vol.23, pp.155-159, 2003.

R. W. Licht, P. Vestergaard, L. V. Kessing, J. K. Larsen, and P. H. Thomsen, Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark, Acta Psychiatrica Scandinavica, vol.43, issue.s419, 2003.
DOI : 10.1034/j.1600-0447.2001.00389.x

H. Autorité-de-santé-teralithe, European Medicines Agency 2011 Valproate, 2011.

J. Angst, P. Weis, P. Grof, P. C. Baastrup, and M. Schou, Lithium Prophylaxis in Recurrent Affective Disorders, The British Journal of Psychiatry, vol.116, issue.535, pp.604-614, 1970.
DOI : 10.1192/bjp.116.535.604

P. C. Baastrup and M. Schou, Lithium As a Prophylactic Agent, Archives of General Psychiatry, vol.16, issue.2, pp.162-172, 1967.
DOI : 10.1001/archpsyc.1967.01730200030005

M. M. Sidor and G. M. Macqueen, An Update on Antidepressant Use in Bipolar Depression, Current Psychiatry Reports, vol.60, issue.11, pp.696-704, 2012.
DOI : 10.1007/s11920-012-0323-6

D. Carvalho and W. , Caract??ristiques sociod??mographiques et cliniques de patients souffrant de troubles bipolaires suivis en ambulatoire en France m??tropolitaine, L'Enc??phale, vol.38, issue.3, pp.211-223, 2012.
DOI : 10.1016/j.encep.2012.04.007

I. Schizophrénie, fr/thematiques/neurosciences-sciences-cognitives- neurologie-psychiatrie/dossiers-d-information, N05CD08 MIDAZOLAM N05CD02 NITRAZEPAM N05BA16 NORDAZEPAM N05BA04 OXAZEPAM N05BA11 PRAZEPAM N05CD07 TEMAZEPAM N05CD05 TRIAZOLAM N05CF02 ZOLPIDEM N05CF01 ZOPICLONE Bilans : codes TNB Biochimique 1609 SANG : IONOGRAMME (NA+K+ EVENTUELLEMENT CL) 1610 SANG : IONOGRAMME COMPLET (NA + K + CL + CO2 + PROTIDES) : CALCIUM